A Randomized, Two-Treatments, Two-Periods, Crossover, Open label, Laboratory-Blind, Single Dose Bioequivalence Study between Vildagliptin/Metformin 50 mg/1000 mg Film Coated Tablets (Sensityn®) and Galvusmet® 50 mg/1000 mg Film Coated Tablets in healthy adults under fed conditions
Saudi National Diabetes Center (SNDC), SAUDI HEALTH COUNCIL, 1st edition; Aug 2021.Saudi National Diabetes Center (SNDC)1st editionAug2021Search in Google Scholar
Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, Khan NB, Al-Khadra A, Al-Marzouki K, Nouh MS, Abdullah M, Attas O, Al-Shahid MS, Al-Mobeireek A. Diabetes mellitus in Saudi Arabia. Saudi Med J. 2004;25:1603–1610.Al-NozhaMMAl-MaatouqMAAl-MazrouYYAl-HarthiSSArafahMRKhalilMZKhanNBAl-KhadraAAl-MarzoukiKNouhMSAbdullahMAttasOAl-ShahidMSAl-MobeireekADiabetes mellitus in Saudi Arabia20042516031610Search in Google Scholar
Eligar VS, Bain SC. A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment. Drug Des. Devel. Ther. 2013;7:893–903.EligarVSBainSCA review of sitagliptin with special emphasis on its use in moderate to severe renal impairment20137893903Search in Google Scholar
NICE. Managing blood glucose in adults with type 2 diabetes. 2016;1–24.NICE2016124Search in Google Scholar
American Diabetes Association. Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers. Clin Diabetes. 2022;40:10–38.American Diabetes AssociationStandards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers2022401038Search in Google Scholar
Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane.Database.Syst.Rev. 2005; CD002966.SaenzAFernandez-EstebanIMataixAAusejoMRoqueMMoherDMetformin monotherapy for type 2 diabetes mellitus2005CD002966Search in Google Scholar
Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab.Vasc.Dis.Res. 2008;5: 157–167.ScarpelloJHHowlettHCMetformin therapy and clinical uses20085157167Search in Google Scholar
Lv Z, Guo Y. Metformin and Its Benefits for Various Diseases. Front Endocrinol.(Lausanne) 2020;11:191.LvZGuoYMetformin and Its Benefits for Various Diseases202011191Search in Google Scholar
Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13:7–18.DeaconCFDipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review201113718Search in Google Scholar
Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care. 2007;30:1335–1343.DruckerDJDipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action20073013351343Search in Google Scholar
Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10:82–90.BolliGDottaFRochotteECohenSEEfficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study2008108290Search in Google Scholar
Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahren B, Byiers S, Shao Q, Dejager S. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11:157–166.FerranniniEFonsecaVZinmanBMatthewsDAhrenBByiersSShaoQDejagerSFifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy200911157166Search in Google Scholar
Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010:27;318–326.FilozofCGautierJFA comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study201027318326Search in Google Scholar
Jeon HJ, Oh, TK. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. Diabetes Metab J. 2011;35:529–535.JeonHJOhTKComparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients201135529535Search in Google Scholar
Mathieu C, Kozlovski P, Paldanius PM, Foley JE, Modgill V, Evans M, Serban C. Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance. Eur Endocrinol. 2017;13: 68–72.MathieuCKozlovskiPPaldaniusPMFoleyJEModgillVEvansMSerbanCClinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance2017136872Search in Google Scholar
American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45:S125–S143.American Diabetes Association Professional Practice CommitteeDrazninBArodaVRBakrisGBensonGBrownFMFreemanRGreenJHuangEIsaacsDKahanSLeonJLyonsSKPetersALPrahaladPReuschJEBYoung-HymanD9.Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022202245S125S143Search in Google Scholar
Del Prato S, Foley JE, Kothny W, Kozlovski P, Stumvoll M, Paldánius PM, Matthews DR. Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. Diabet Med. 2014;31:1178–1184.Del PratoSFoleyJEKothnyWKozlovskiPStumvollMPaldániusPMMatthewsDRStudy to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial20143111781184Search in Google Scholar
Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394:1519–1529.MatthewsDRPaldániusPMProotPChiangYStumvollMDel PratoSVERIFY study groupGlycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial201939415191529Search in Google Scholar